Data in NEJM show Novartis drug Aclasta® significantly reduced the risk of fracture in men with osteoporosis with once-yearly infusion
1 November 2012 | By Edelman
NEJM published results...
List view / Grid view
News
More than £1 billion to be invested in UK science and research
1 November 2012 | By BIS Press Office
New science investment will make sure UK competes and thrives in global race...
Bristol-Myers Squibb receives positive decision from NICE for YERVOY® (ipilimumab)
1 November 2012 | By Bristol-Myers Squibb Company
NICE has decided to recommend YERVOY®...
GSK supports BMJ commitment on clinical trial data transparency
31 October 2012 | By GlaxoSmithKline
“GSK fully supports the commitment made by BMJ to drive greater transparency of clinical trial data..."
Wealth of worldwide evidence on Pradaxa® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented
31 October 2012 | By Boehringer Ingelheim
Results from RELY-ABLE®...
Novo Nordisk increased operating profit by 34% in the first nine months of 2012
31 October 2012 | By Novo Nordisk
Sales grew 18% driven by Victoza®, NovoRapid® and Levemir®...
Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer
31 October 2012 | By Roche
The EC has approved Avastin...
Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million
31 October 2012 | By Novartis
Novartis announced the construction of a new state-of-the-art biotechnology production site...
Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D
31 October 2012 | By Boehringer Ingelheim
Patients and physicians may have several innovative respiratory treatments available in the coming years...
Alzheimer’s, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration
31 October 2012 | By AstraZeneca
Funding for 15 research projects...
Genzyme announces publication of LEMTRADA (alemtuzumab) pivotal studies in The Lancet
31 October 2012 | By
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications...
Gilead’s once-daily novel prodrug for the treatment of HIV meets 24-week primary objective in Phase 2 study
31 October 2012 | By Gilead Sciences
Data support tenofovir alafenamide fumarate as component of future single tablet HIV regimens...
Health Canada and Swissmedic lift precautionary holds on Novartis seasonal influenza vaccines
31 October 2012 | By Novartis
Novartis welcomes the decisions by Health Canada and Swiss Agency for Therapeutic Products, Swissmedic...
Biogen Idec and Sobi announce positive top-line results from Phase 3 study investigating long-lasting recombinant Factor VIII Fc fusion protein in Hemophilia A
31 October 2012 | By Biogen Idec
Biogen Idec and Swedish Orphan Biovitrum announced positive results from A-LONG...
Tecan and TAP Biosystems to automate RAFT™ 3D cell culturing on the Freedom EVO®
30 October 2012 | By kdm communications limited
Tecan and TAP Biosystems, a leading supplier of innovative cell culture systems, have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform. Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D…
